Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Leukemia, Myeloid, Acute 2Leukemia 2Urinary Bladder Neoplasms 1Stomach Neoplasms 1Sezary Syndrome 1Sarcoma 1Recurrence 1Prostatic Neoplasms 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasms 1Neoplasm Metastasis 1Myelodysplastic Syndromes 1Mycosis Fungoides 1Melanoma 1Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell, Cutaneous 1Lung Neoplasms 1Liver Neoplasms 1Leukemia-Lymphoma, Adult T-Cell 1Leukemia, Prolymphocytic, T-Cell 1Kidney Neoplasms 1High-risk Leukemias 1Glioblastoma 1Esophageal Neoplasms 1Disease 1Colorectal Neoplasms 1Carcinoma, Bronchogenic 1Bronchiolitis Obliterans Syndrome 1

Interventions

ibrutinib 5ofatumumab 4Imatinib Mesylate 4Dasatinib 4nilotinib 3fludarabine 3bosutinib 3asciminib 3Rituximab 3Cyclophosphamide 3ruxolitinib 2obinutuzumab 2Sirolimus 2Mycophenolic Acid 2KW-2478 2Filgrastim 2Alemtuzumab 2posaconazole 1ponatinib 1pegfilgrastim 1oblimersen 1montelukast 1mocetinostat 1milatuzumab 1lonafarnib 1fenebrutinib 1abexinostat 1Whole-Body Irradiation 1Voriconazole 1Vision, Ocular 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Bronchiolitis Obliterans Syndrome × Interleukin-15 × Other hematologic neoplasm × Clear all
NCT03759184 2022-03-22

Human IL-15 (rhIL-15) and Obinutuzumab for Relapsed and Refractory Chronic Lymphocyte Leukemia

National Institutes of Health Clinical Center (CC)

Phase 1 Terminated
1 enrolled 13 charts
Other hematologic neoplasm

Bronchiolitis Obliterans Syndrome, Leukemia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡